Inosine pranobex, a medication with established clinical use against herpes simplex and human papillomavirus, may offer new therapeutic options for COVID-19, according to research published in the International Journal of Infectious Diseases. Dr. Simon Reich’s analysis examines how the drug’s dual mechanisms—immune system modulation and direct antiviral effects—could translate to SARS-CoV-2 treatment. The drug’s existing approval for other viral infections positions it as a candidate for expedited clinical evaluation. However, researchers emphasize that while preliminary findings are encouraging, comprehensive clinical trials remain essential to confirm safety and efficacy specifically for COVID-19. This investigation represents a continuation of the scientific community’s broader efforts to identify effective therapeutic strategies four years into the pandemic. Read the full article on GMJ Newsroom.
Was this article helpful?
